Download PDF
TumorDiagnostik & Therapie 2017; 38(03): 172-177
DOI: 10.1055/s-0043-101185
Schwerpunkt Neuroonkologie
© Georg Thieme Verlag KG Stuttgart · New York

Maligne Gliome: Therapieoptionen bei Kindern und Jugendlichen

André O. von Bueren
1   Unité d´onco-hématologie pédiatrique, Departement de l´enfant et de l´adolescent, Hôpitaux Universitaire Genève, Genf, Schweiz
,
Maria Wiese
2   Abteilung für Pädiatrische Hämatologie und Onkologie, Universitätsmedizin Göttingen
,
Gerrit Gielen
3   Institut für Neuropathologie, Universitätsklinikum Bonn, Bonn
,
Christof M. Kramm
4   Abteilung für Pädiatrische Hämatologie und Onkologie, Universitätsmedizin Göttingen
› Author Affiliations
Further Information

Publication History

Publication Date:
28 April 2017 (online)

Also available at
    Permissions and Reprints

Neben den Eckpfeilern einer konventionellen onkologischen Therapie – Tumoroperation, Radio- und Chemotherapie – beleuchtet dieser Beitrag auch zielgerichtete Therapiestrategien sowie die Neuentwicklungen im immuntherapeutischen Bereich speziell bei pädiatrischen hochgradigen Gliomen.
 

  • Literatur

  • 1 Ostrom QT. Gittleman H. Fulop J. et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro Oncol 2015; 17: 1-62
    CrossrefPubMedGoogle Scholar
  • 2 Hargrave D. Bartels U. Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006; 7: 241-248
    CrossrefPubMedGoogle Scholar
  • 3 Castel D. Phillipe C. Calmon R. et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 2015; 130: 815-827
    CrossrefPubMedGoogle Scholar
  • 4 Louis DN. Perry A. Reifenberger G. et al. WHO classification of tumours of the central nervous system.Revised. 4th edition. Lyon: International Agency for Research on Cancer; 2016
    Google Scholar
  • 5 Louis DN. WHO classification of tumours of the central nervous system. 4th ed. Lyon: International Agency for Research on Cancer; 2007
    Google Scholar
  • 6 Duffner PK. Krischer JE. Burger PC. et al. Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol 1996; 28: 245-256
    PubMedGoogle Scholar
  • 7 Dufour C. Grill J. Lellouch-Tubiana A. et al. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur J Cancer 2006; 42: 2939-2945
    CrossrefPubMedGoogle Scholar
  • 8 Geyer JR. Finlay JL. Boyett JM. et al. Survival of infants with malignant astrocytomas. A Report from the Childrens Cancer Group. Cancer 1995; 75: 1045-1050
    CrossrefPubMedGoogle Scholar
  • 9 Albright AL. Sposto R. Holmes E. et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 2000; 47: 879-887
    CrossrefPubMedGoogle Scholar
  • 10 Wisoff JH. Boyett JM. Berger MS. et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-59
    CrossrefPubMedGoogle Scholar
  • 11 Finlay JL. Wisoff JH. The impact of extent of resection in the management of malignant gliomas of childhood. Childs Nerv Syst 1999; 15: 786-788
    CrossrefPubMedGoogle Scholar
  • 12 Campbell JW. Pollack IF. Martinez AJ. et al. High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 1996; 38: 258-264
    CrossrefPubMedGoogle Scholar
  • 13 Kramm CM. Wagner S. van Gool S. et al. Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res 2006; 26: 3773-3779
    PubMedGoogle Scholar
  • 14 Wolff JE. Gnekow AK. Kortmann RD. et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 2002; 94: 264-271
    CrossrefPubMedGoogle Scholar
  • 15 Kotecha RS. Burley K. Junckerstorff R. et al. Chemotherapy increases amenability of surgical resection in congenital glioblastoma. Pediatr Hematol Oncol 2012; 29: 538-544
    CrossrefPubMedGoogle Scholar
  • 16 Montemurro N. Second surgery for recurrent glioblastoma: A concise overview of the current literature. Clin Neurol Neurosurg 2016; 142: 60-64
    CrossrefPubMedGoogle Scholar
  • 17 Brandes AA. Bartolotti M. Tosoni A. et al. Patient outcomes following second surgery for recurrent glioblastoma. Future Oncol 2016; 12: 1039-1044
    CrossrefPubMedGoogle Scholar
  • 18 Giordano M. Samii A. Lawson McLean A. et al. Intraoperative magnetic resonance imaging in pediatric neurosurgery: safety and utility. J Neurosurg Pediatr 2017; 19: 77-84
    PubMedGoogle Scholar
  • 19 Barbagallo GM. Certo F. Heiss K. et al. 5-ALA fluorescence-assisted surgery in pediatric brain tumors: report of three cases and review of the literature. Br J Neurosurg 2014; 28: 750-754
    CrossrefPubMedGoogle Scholar
  • 20 Preuß M. Renner C. Krupp W. et al. The use of 5-aminolevulinic acid fluorescence guidance in resection of pediatric brain tumors. Childs Nerv Syst 2013; 29: 1263-1267
    CrossrefPubMedGoogle Scholar
  • 21 Gillingham FJ. Yamashita J. The effect of radiotherapy for glioblastoma: a review of 516 cases (author's transl). No Shinkei Geka 1975; 3: 329-336
    PubMedGoogle Scholar
  • 22 Sposto R. Ertel IJ. Jenkin RD. et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. J Neuro-Oncol 1989; 7: 165-177
    CrossrefPubMedGoogle Scholar
  • 23 Stupp R. Mason WP. van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
    CrossrefPubMedGoogle Scholar
  • 24 Cohen KJ. Heidemann RL. Zhou T. et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 2011; 13: 410-416
    CrossrefPubMedGoogle Scholar
  • 25 Cohen KJ. Pollack IF. Zhou T. et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011; 13: 317-323
    CrossrefPubMedGoogle Scholar
  • 26 Morales La Madrid A. Hashizume R. Kieran MW. Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic. Front Oncol 2015; 5: 148
    PubMedGoogle Scholar
  • 27 Jakacki RI. Cohen KJ. Buxton A. et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol 2016; 18: 1442-1450
    CrossrefPubMedGoogle Scholar
  • 28 Hegi ME. Diserens AC. Gorlia T. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003
    CrossrefPubMedGoogle Scholar
  • 29 Janssens GO. Gandola L. Bolle S. et al. Survival benefit for patients with DIPG undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 2017; 73: 38-47
    PubMedGoogle Scholar
  • 30 Muller K. Scheithauer H. Pietschmann S. et al. Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group. Radiat Oncol 2014; 9: 177
    CrossrefPubMedGoogle Scholar
  • 31 Leroy R. Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. Int J Radiat Oncol Biol Phys 2016; 95: 267-278
    CrossrefPubMedGoogle Scholar
  • 32 Jones C. Karajannis MA. Jones DTW. et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol 2016; DOI: doi.org/10.1093/neuonc/now101.
    CrossrefPubMedGoogle Scholar
  • 33 https://www.dkfz.de/en/inform
    PubMed
  • 34 Ardon H. de Vleeschouwer S. van Calenbergh F. et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 2010; 54: 519-525
    PubMedGoogle Scholar
  • 35 Rutkowski S. de Vleeschouwer S. Kaempgen E. et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004; 91: 1656-1662
    CrossrefPubMedGoogle Scholar
  • 36 Freeman AI. Zakay-Rones Z. Gomori JM. et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006; 13: 221-228
    CrossrefPubMedGoogle Scholar
  • 37 Brown CE. Alizadeh D. Starr R. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016; 375: 2561-2569
    CrossrefPubMedGoogle Scholar
  • 38 Bouffet E. Larouche V. Campbell BB. et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol 2016; 34: 2206-2211
    CrossrefPubMedGoogle Scholar
  • 39 Bender S. Gronych J. Warnatz HJ. et al. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med 2016; 22: 1314-1320
    CrossrefPubMedGoogle Scholar